# A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

> **NCT07724340** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Antag Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Adults With Overweight/Obesity and Type 2 Diabetes

## Interventions

- **DRUG:** AT673 low dose
- **DRUG:** AT673 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07724340
- **Lead sponsor:** Antag Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-19
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724340, "A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07724340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*